Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 4/20 | 0.33 |
| ▸ | CASP1 | P29466 | 4/20 | 0.33 |
| ▸ | CASP7 | P55210 | 4/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669183 | 0.82 | KDM5B (0.42) | CYP1A2CYP3A4MEN1CYP2C9CYP2C19 | |
| SCHEMBL1669100 | 0.77 | ALDH1A1 (0.33) | CYP1A2CYP3A4MEN1CYP2C9CYP2C19 | |
| SCHEMBL1672314 | 0.76 | CYP1A2 (0.33) | CYP1A2CYP3A4MEN1CYP2C9CYP2C19 | |
| SCHEMBL1669470 | 0.76 | ALDH1A1 (0.37) | CYP1A2CYP3A4MEN1CYP2C9CYP2C19 | |
| SCHEMBL12198932 | 0.76 | CYP3A4 (0.31) | CYP1A2CYP3A4MEN1CYP2C9CYP2C19 | |
| SCHEMBL1669226 | 0.76 | XIAP (0.32) | CYP1A2CYP3A4MEN1CYP2C9CYP2C19 | |
| SCHEMBL1669200 | 0.75 | NPC1 (0.39) | ALDH1A1USP2RIPK1TSHRLMNA | |
| SCHEMBL1669094 | 0.75 | ALDH1A1 (0.33) | HDAC6CYP1A2CYP3A4MEN1CYP2C9 | |
| SCHEMBL1669239 | 0.75 | ADORA2A (0.32) | CYP1A2CYP3A4MEN1CYP2C9CYP2C19 | |
| SCHEMBL417504 | 0.74 | KCNH2 (0.51) | MEN1CYP2C9KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | claimed |
| EP-2488517-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | claimed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | claimed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | claimed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383639-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2488517-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110245241-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046873-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245241-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | HDAC1 908/4885HDAC6 3454/4885CYP1A2 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.